XOMA Royalty Corporation - Asset Resilience Ratio
XOMA Royalty Corporation (XOMA) has an Asset Resilience Ratio of 0.18% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read XOMA Royalty Corporation (XOMA) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1998–2025)
This chart shows how XOMA Royalty Corporation's Asset Resilience Ratio has changed over time. See XOMA Royalty Corporation (XOMA) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down XOMA Royalty Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see XOMA total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $494.00K | 0.18% |
| Total Liquid Assets | $494.00K | 0.18% |
Asset Resilience Insights
- Limited Liquidity: XOMA Royalty Corporation maintains only 0.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
XOMA Royalty Corporation Industry Peers by Asset Resilience Ratio
Compare XOMA Royalty Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Dyne Therapeutics Inc
NASDAQ:DYN |
Biotechnology | 20.28% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX |
Biotechnology | 0.00% |
|
LegoChem Biosciences Inc
KQ:141080 |
Biotechnology | 55.88% |
Annual Asset Resilience Ratio for XOMA Royalty Corporation (1998–2025)
The table below shows the annual Asset Resilience Ratio data for XOMA Royalty Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.14% | $382.00K | $272.70 Million | -1.45pp |
| 2024-12-31 | 1.59% | $3.53 Million | $221.28 Million | +1.53pp |
| 2023-12-31 | 0.07% | $161.00K | $234.30 Million | -0.17pp |
| 2022-12-31 | 0.24% | $335.00K | $140.38 Million | -0.23pp |
| 2021-12-31 | 0.46% | $774.00K | $166.56 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $125.28 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $44.94 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $28.68 Million | -- |
| 2015-12-31 | 0.66% | $496.00K | $74.88 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $89.63 Million | -- |
| 2013-12-31 | 14.83% | $19.99 Million | $134.78 Million | -23.01pp |
| 2012-12-31 | 37.84% | $39.99 Million | $105.68 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $78.04 Million | -- |
| 2008-12-31 | 1.93% | $1.30 Million | $67.17 Million | -17.01pp |
| 2007-12-31 | 18.94% | $16.07 Million | $84.81 Million | -1.15pp |
| 2006-12-31 | 20.09% | $18.38 Million | $91.48 Million | -11.23pp |
| 2005-12-31 | 31.32% | $22.73 Million | $72.58 Million | +30.22pp |
| 2004-12-31 | 1.10% | $511.00K | $46.26 Million | +0.74pp |
| 2003-12-31 | 0.37% | $436.00K | $118.85 Million | -0.18pp |
| 2002-12-31 | 0.54% | $391.00K | $71.78 Million | +0.17pp |
| 2001-12-31 | 0.37% | $320.00K | $86.11 Million | -0.01pp |
| 2000-12-31 | 0.38% | $172.00K | $45.21 Million | -43.59pp |
| 1998-12-31 | 43.97% | $16.40 Million | $37.30 Million | -- |
About XOMA Royalty Corporation
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with co… Read more